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Low factor XIII levels after 
intravenous thrombolysis predict 
short-term mortality in ischemic 
stroke patients
Edina Gabriella Székely1, Katalin Réka Czuriga-Kovács2, Zsuzsanna Bereczky1, Éva Katona1, 
Zoltán András Mezei1, Attila Nagy3, Noémi Klára Tóth1, Ervin Berényi4, László Muszbek1, 
László Csiba2,5 & Zsuzsa Bagoly1,5
In this observational study we investigated whether levels of factor XIII (FXIII) and its major 
polymorphisms affect the outcome of thrombolysis by recombinant tissue plasminogen activator (rtPA) 
in acute ischemic stroke (AIS) patients. Study cohort included 132 consecutive AIS patients undergoing 
i.v. thrombolysis within 4.5 h of symptom onset. Blood samples taken on admission, immediately 
after and 24 h after therapy were analyzed for FXIII activity and antigen levels. FXIII-A p.Val34Leu, 
p.Tyr204Phe, FXIII-B p.His95Arg and intron K(IVS11 + 144) polymorphisms were genotyped. 
Neurological deficit was assessed using the National Institutes of Health Stroke Scale. Intracranial 
hemorrhage was classified according to ECASSII criteria. Long-term functional outcome was defined at 
3 months post-event by the modified Rankin scale. FXIII levels showed a gradual decrease immediately 
after thrombolysis and 24 h later, which was not related to therapy-associated bleeding. In a multiple 
logistic regression model, a FXIII level in the lowest quartile 24 h post-lysis proved to be an independent 
predictor of mortality by 14 days post-event (OR:4.95, 95% CI:1.31–18.68, p < 0.05). No association 
was found between the investigated FXIII polymorphisms and therapeutic outcomes. In conclusion, our 
findings indicate that FXIII levels 24 h after thrombolysis might help to identify patients at increased risk 
for short-term mortality.
Acute ischemic stroke (AIS) is a leading cause of death or disability in all developed countries1. Today, the most 
effective pharmacological therapy to improve functional outcomes is the lysis of thrombi using recombinant 
tissue plasminogen activator (rtPA) within 4.5 hours after the onset of symptoms2. Although this intervention 
has been used for many decades, little is known why in some patients thrombolysis is less efficient and which 
are the factors promoting non-desirable side effects in others. In a subset of patients thrombolytic therapy is 
inefficient due to the failure of recanalization of the closed vessel and no clinical improvement is observed3. On 
the other hand, approximately 7–8% of patients develop potentially fatal intracranial hemorrhage, despite the 
fact that those eligible for therapy are carefully selected to minimize bleeding risk. In most cases, these compli-
cations cannot be foreseen at the initiation of therapy and their occurrence remains unexplained. It is plausible 
that effectiveness as well as adverse effects of the thrombolytic agent could depend on hemostatic and fibrinolytic 
factors influencing the structure of thrombi and the susceptibility to lysis. With the introduction of mechanical 
thrombectomy in the management of acute stroke care, today it is becoming important to identify patients who 
are at risk of worse thrombolysis outcomes and would benefit from alternative treatments4.
Blood coagulation factor XIII (FXIII) is a key player in the last step of the coagulation cascade determining 
clot stability5–7. FXIII is a tetramer consisting of two, potentially active A subunits (FXIII-A) and two carrier/
inhibitory B subunits (FXIII-B). Its activation occurs in the last step of the clotting cascade by thrombin and 
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Ca2+ 8. The active form (FXIIIa) plays a crucial role in protecting the clot against prompt fibrinolytic degradation, 
which is achieved by at least three major ways. First, FXIIIa cross-links α2-plasmin inhibitor (α2-PI) and perhaps 
other plasma components to fibrin, which effectively hinders its proteolytic degradation by plasmin. Second, 
FXIIIa cross-links fibrin α-chains into a high molecular weight α-polymers, which most likely has a direct effect 
on the susceptibility of fibrin clot to lysis. Third, cross-linking of fibrin by FXIIIa decreases the binding of plas-
minogen to fibrin, and consequently, decreases plasminogen activation by tPA9. On the other hand, deficiency 
of FXIII leads to a life-long bleeding disorder and in many cases severe or fatal intracranial hemorrhage is a 
prominent feature of the disease10. FXIII has a number of common polymorphisms: five have been described in 
FXIII-A (p.Val34Leu, p.Tyr204Phe, p.Leu564Pro, p.Val650Ile, p.Glu651Gln), two in FXIII-B (p.His95Arg and 
c.1952 + 144 C > G in intron K)6. Today, growing evidence supports the role of FXIII as a risk factor in ath-
erothrombotic disorders9. Among FXIII polymorphisms, the relation of FXIII-A p.Val34Leu with the risk of 
thrombotic diseases has been intensively investigated5,6,9. However, only few reports are available on the relation 
of ischemic stroke and FXIII levels and/or its polymorphisms, as most studies include patients with coronary 
artery disease and/or myocardial infarction9,11. Moreover, although the association of FXIII levels and/or its com-
mon polymorphisms with the outcome of thrombolytic therapy in AIS is biologically plausible, surprisingly, to 
date, only few studies involving relatively small cohort of patients have been published12–16. Here we aimed to 
determine the impact of FXIII levels measured before and during the course of thrombolysis as well as common 
FXIII-A and FXIII-B polymorphisms on therapeutic outcomes in an AIS population undergoing thrombolysis 
within the therapeutic time-frame.
Results
Study population. Baseline characteristics of patients and stroke outcomes are summarized in Table 1. 
A total of 132 consecutive AIS patients undergoing thrombolysis were included in the study. Mean age was 
69.0 ± 12.2 years, and 58.3% were men. The median NIHSS score on admission was 8 (interquartile range: 5–14). 
According to the TOAST criteria, most patients suffered a large vessel thrombosis (n = 49, 37.1%). Average time 
from symptom onset to treatment with rtPA was less than 3 h in the cohort and the duration of thrombolysis 
was approximately one hour for each patient. In case of 7 patients intravenous thrombolytic therapy was supple-
mented with intraarterial thrombolysis according to the standard protocol; the final dose of rtPA and the duration 
of thrombolysis was not significantly different for these patients as compared to the rest of the study group.
Favorable short-term and long-term functional outcomes were observed in 53 (40.2%) and 46 (34.8%) 
cases, respectively. Stroke-associated mortality by day 7, day 14 and by the end of the 3rd month post-event was 
observed in 5 (3.8%), 18 (13.6%), and 29 (22.0%) cases, respectively. Therapy-associated bleeding complication 
was detected in 13 cases (7 patients presented with aSICH, 6 patients with SICH). One patient has died following 
intracerebral hemorrhage.
The influence of thrombolysis on FXIII levels. Mean FXIII activity and antigen levels before and during 
the course of thrombolysis are shown in Table 2. On admission (before thrombolysis) a considerable number of 
patients (n = 39, 29.5%; data not shown in Table) had FXIII levels above the upper limit of the reference interval 
(above 143% or 28 mg/l). FXIII levels showed a gradual decrease after thrombolysis; at 24 h post-lysis significantly 
lower FXIII levels were detected as compared to initial values. Strong correlation was observed between FXIII 
activity and FXIII antigen levels at all investigated occasions (time points A, B and C: Pearson r = 0.915, p < 0.001; 
r = 0.919, p < 0.001 and r = 0.917, p < 0.001, respectively; data not shown in Table).
Association of FXIII levels on admission with stroke characteristics. FXIII levels on admission 
showed no association with the severity of the stroke (Table 3) and no correlation was observed between FXIII 
levels and NIHSS scores on admission (Pearson r = −0.09, p = 0.28). FXIII activity was significantly higher in 
case of atherothrombotic stroke as compared to strokes of cardioembolic origin (Table 3). FXIII activity and 
antigen levels showed a weak negative association with the age of the patients (Pearson r = −0.299, p < 0.001 and 
r = −0.286, p < 0.001, respectively; data not shown in Table). FXIII antigen levels were significantly higher in 
active smokers vs. never-smokers (24.60 mg/l vs. 21.15 ± 0.9 mg/l, respectively, p < 0.05; data not shown in Table). 
No correlation was observed between FXIII levels and any measured routine clinical chemistry, hemostasis and 
hematology parameters. No correlation was observed between FXIII levels measured at any time points and data 
obtained from CT imaging analysis (ASPECTS; data not shown). No correlation was observed between FXIII 
activity/antigen levels measured on admission and the elapsed time between symptom onset to thrombolysis 
treatment (r = 0.081, p = 0.186 and r = 0.061, p = 0.251, respectively; data not shown in Table).
Association of FXIII levels during thrombolysis and therapy outcomes. FXIII levels before the ini-
tiation of the therapy (time point A) or immediately after thrombolysis (time point B) showed no association with 
short-term functional outcomes (Table 4). On the contrary, at 24 h after thrombolysis (time point C), significantly 
lower FXIII levels were detected in those patients who died within the first week following treatment. FXIII levels 
were remarkably low in these patients, approximately 50% as compared to values measured in patients with other 
outcomes. Mortality and low FXIII levels were not associated with bleeding complications. On the other hand, no 
difference was observed in the FXIII levels of patients with any other outcomes except for mortality (i.e. favorable 
outcome vs. no change or unfavorable outcome; data not shown). Patients experiencing bleeding after therapy 
were separately handled during the analysis due to different assumed underlying pathomechanisms.
Low FXIII levels were associated with mortality by day 14 post-event as well. When studying the baseline 
characteristics of patients grouped according to mortality by the end of the 2nd week, it was found that besides 
the NIHSS on admission, only FXIII levels measured before and 24 h after thrombolysis were significantly dif-
ferent in the two groups (Table 5). Similar results were observed when FXIII levels were investigated in terms of 
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Values
Number of patients 132
Male 77 (58.3)
Age (years) 69.0 ± 12.2
Risk factors
   Hypertension 101 (76.5)
   Atrial fibrillation/flutter 35 (26.5)
   Hyperlipidaemia 82 (62.1)
   Diabetes mellitus 40 (30.3)
   Previous stroke 42 (31.8)
   Active smoker 32 (24.2)
Stroke severity
   NIHSS 0–5 37 (28.0)
   NIHSS 6–10 48 (36.4)
   NIHSS 11–15 21 (15.9)
   NIHSS >15 23 (17.4)
Stroke etiology (TOAST)
   Small vessel occlusion 14 (10.6)
   Large vessel thrombosis 49 (37.1)
   Cardioembolic 27 (20.5)
   Undetermined 42 (31.8)
Time from symptom onset to treatment with rtPA (min) 160 ± 46
Dose of rtPA (mg)
   Intravenous rtPA (n = 125) 68.2 ± 14.9
   Intravenous and intraarterial rtPA (n = 7) 61.6 ± 14.7
Duration of thrombolysis (min) 64 ± 10
Imaging data (median; total range)
   ASPECT score on admission 10 (7–10)
   ASPECT score at 24 h 9 (0–10)
Short-term functional outcome
   Favorable 53 (40.2)
   No change 47 (36.6)
   Unfavorable 21 (15.9)
   Death 5 (3.8)
   Undetermined 6 (4.5)
Long-term functional outcome
   mRS 0–1 46 (34.8)
   mRS 2–5 34 (25.8)
   mRS 6 (death) 29 (22.0)
   Undetermined 23 (17.4)
Mortality by day 14 18 (13.6)
Intracerebral hemorrhage (ECASS II)
   aSICH 7 (5.3)
   SICH 6 (4.5)
Table 1. Baseline characteristics and outcomes of patients. Data are expressed as mean ± standard deviation 
or number (percentage) unless otherwise stated. n, number; NIHSS, National Institute of Health Stroke Scale; 
TOAST, Trial of Org 10172 in Acute Stroke Treatment; rtPA, recombinant tissue plasminogen activator; 
ASPECT, Alberta Stroke Program Early CT score; mRS, modified Rankin score; ECASS II, European 
Cooperative Acute Stroke Study II; aSICH, asymptomatic intracranial hemorrhage; SICH, symptomatic 
intracranial hemorrhage.
Before 
thrombolysis (A)
Immediately after 
thrombolysis (B)
24 h after 
thrombolysis (C)
P-value* 
A vs. C
FXIII activity (%) 126.1 ± 36.1 124.7 ± 33.8 116.6 ± 35.0 0.034
FXIII-A2B2 (mg/l) 22.3 ± 7.6 21.4 ± 6.8 19.6 ± 6.4 0.002
Table 2. The influence of thrombolysis on factor XIII (FXIII) levels. Results are expressed as mean ± standard 
deviation. *ANOVA with Bonferroni post hoc test.
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functional outcomes at 3 months post-event (Fig. 1). FXIII levels 24 h after lysis were significantly lower in those 
patients who died by the end of the 3rd month after the event (mRS 6). In order to test whether a low FXIII level 
measured 24 h after thrombolysis is an independent predictor of short- and long-term mortality of patients, back-
ward multiple regression analysis for mortality was performed including all potentially relevant risk factors and 
confounders (Table 6). NIHSS score on admission was found to be an independent predictor of mortality by 14 
days (OR: 1.12; 95% CI: 1.02–1.23, p = 0.013) and by the end of the 3rd month after the event (OR: 1.16; 95% CI: 
1.05–1.28, p = 0.004). FXIII levels in the lowest quartile 24 h after thrombolysis were found to be an independent 
predictor of short-term mortality (OR: 4.95; 95% CI: 1.31–18.68, p = 0.018). On the other hand, low FXIII levels 
24 h after thrombolysis did not prove to be an independent predictor of mortality at 3 months post-stroke (OR: 
1.88; 95% CI: 0.55–6.41, p = 0.311).
FXIII levels are not associated with therapy-associated symptomatic or asymptomatic intrac-
erebral hemorrhage. In patients suffering therapy-associated intracerebral bleeding complications (n = 13, 
Table 4), FXIII levels during thrombolysis were surprisingly similar to that observed in patients with other 
outcomes except for death. FXIII levels showed no significant difference at any measured time points between 
patients not experiencing hemorrhage and patients with SICH or aSICH (Supplementary Table S1). In this cohort, 
only one patient with therapy-associated hemorrhage had low FXIII levels (FXIII activity at time point A: 45.9%, 
B: 50.2%, C: 39.9%); heterozygous FXIII-A deficiency was ruled out in this patient by direct fluorescent sequenc-
ing of F13A1 gene (data not shown). Except for this single patient, FXIII levels were within or above the reference 
range at all measured time points in patients suffering symptomatic or asymptomatic bleeding as side-effect. One 
patient had died due to therapy-associated SICH by day 1, in this case, FXIII levels were also within the reference 
interval (FXIII activity at time point A: 107.7%, time point B: 104.5%).
FXIII polymorphisms, stroke characteristics and thrombolysis outcomes. Allele frequencies of 
the common FXIII-A and FXIII-B polymorphisms were not significantly different in this AIS patient population 
as compared to a large cohort of population control group tested earlier17,18 (data not shown). In agreement with 
previous findings6, the FXIII-A p.Val34Leu, FXIII-A p.Tyr204Phe, FXIII-B p.His95Arg polymorphisms had no 
Severity of Stroke
NIHSS 0–5 
(n = 37)
NIHSS 6–10 
(n = 48)
NIHSS 11–15 
(n = 21)
NIHSS > 15 
(n = 23) P-value*
FXIII activity (%) 129.7 ± 39.9 126.2 ± 39.6 125.6 ± 26.4 120.5 ± 32.3 0.808
FXIII-A2B2 (mg/l) 23.1 ± 7.8 22.6 ± 9.5 21.8 ± 5.0 21.1 ± 5.4 0.805
Etiology of Stroke
Small vessel 
infarcts 
(n = 14)
Large vessel 
thrombosis 
(n = 49)
Cardio-embolic 
(n = 27)
P-value† 
small vessel 
infarcts vs. 
cardioembolic
P-value† 
atherothrombotic 
vs. cardioembolic
FXIII activity (%) 145.6 ± 33.4 130.5 ± 38.3 117.5 ± 24.0 0.038 0.012
FXIII-A2B2 (mg/l) 25.5 ± 7.4 22.8 ± 8.3 20.8 ± 4.8 0.160 0.058
Table 3. Association between factor XIII (FXIII) levels before thrombolysis and the severity and etiology of the 
stroke. Results are expressed as mean ± standard deviation. NIHSS, National Institute of Health Stroke Scale; n, 
number of patients. *Univariate analysis (ANOVA); †ANOVA with Bonferroni post hoc test; atherothrombotic: 
small vessel infarcts + large vessel thrombosis.
Favorable 
outcome (n = 51)
No change 
(n = 42)
Unfavorable 
outcome (n = 16)
Death* 
(n = 4)
Intracerebral 
hemorrhage (n = 13)
P-value† death vs. 
all other outcomes
P-value†,‡ death vs. 
all other outcomes
Before thrombolysis (A)
   FXIII activity (%) 127.3 ± 35.2 128.2 ± 41.1 128.1 ± 26.3 100.0 ± 28.7 125.2 ± 36.9 0.129 0.340
   FXIII-A2B2 (mg/l) 22.9 ± 8.9 22.4 ± 7.7 22.7 ± 4.4 18.3 ± 5.5 21.6 ± 5.99 0.165 0.416
Immediately after thrombolysis (B)
   FXIII activity (%) 123.1 ± 33.2 130.1 ± 35.9 123.3 ± 31.9 111.3 ± 18.8 119.3 ± 38.4 0.256 0.596
   FXIII-A2B2 (mg/l) 21.2 ± 6.5 22.4 ± 7.8 20.3 ± 5.5 20.1 ± 4.2 20.8 ± 7.8 0.335 0.702
24 hours after thrombolysis (C)
   FXIII activity (%) 115.8 ± 28.2 122.0 ± 40.6 116.0 ± 33.8 60.0 ± 28.9 119.9 ± 40.4 0.003 0.009
   FXIII-A2B2 (mg/l) 20.0 ± 5.3 19.9 ± 7.6 19.5 ± 5.8 9.7 ± 5.3 19.1 ± 6.9 0.006 0.014
Table 4. Association of factor XIII (FXIII) levels during thrombolysis with short-term functional outcomes. 
Short-term functional outcomes were assessed at 7 days post-event. Results are expressed as mean ± standard 
deviation. n, number; favorable outcome: a decrease in NIHSS score by at least 4 points or to 0 by day 7; no 
change: a change in NIHSS score less than 4 points by day 7; unfavorable outcome: an increase in NIHSS 
score by at least 4 points by day 7; *stroke-associated death excluding death due to intracerebral hemorrhage; 
†ANOVA with Bonferroni post hoc test; ‡adjusted to age and sex in the statistical model.
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influence on FXIII levels (data not shown). Carriers of the FXIII-B intron K nt29756 G allele showed signifi-
cantly lower FXIII levels as compared to non-carriers (FXIII activity: 114.5 ± 30.9% vs. 130.46 ± 36.9%, p = 0.021, 
respectively and FXIII antigen levels: 19.26 ± 1.2 vs. 23.5 ± 0.75, p = 0.004, respectively), but after adjustment to 
confounders (age, CRP, smoking), differences were not statistically significant among the two groups (data not 
shown in Table). None of the investigated factor XIII polymorphisms were associated significantly with stroke 
severity, unfavorable short-term or long-term outcomes of therapy, therapy-associated symptomatic intracranial 
hemorrhage and mortality (Table 7). In case of FXIII-A p.Val34Leu polymorphism, a trend could be observed 
showing that carriers of the Leu allele might be protected against unfavorable short-term outcomes (OR: 0.33; 
95% CI: 0.09–1.10), but the association was not statistically significant (p = 0.072).
Discussion
Despite the fact that activated FXIII plays a prominent role in the protection against fibrinolysis by plasmin, this 
is the first comprehensive study investigating FXIII activity and antigen levels during thrombolysis in AIS patients 
and the association of FXIII levels and polymorphisms with clinical outcomes. Here we show that FXIII activity 
and antigen levels decrease gradually during thrombolysis. The mechanism involved in such reduction of FXIII 
Variables Survival (n = 114) Death (n = 18) P-value
Age, years 68.0 (58.0–79.0) 75.5 (63.0–83.3) 0.130
Male 67 (58.8) 11 (61.1) 0.851
Arterial hypertension 87 (76.3) 13 (73.7) 0.707
Atrial fibrillation 28 (24.6) 7 (38.9) 0.201
Hyperlipidaemia 73 (64.0) 9 (50.0) 0.254
Diabetes mellitus 32 (28.1) 8 (44.4) 0.160
Previous stroke 39 (34.2) 3 (16.7) 0.138
Active smoker 28 (24.6) 4 (22.2) 0.830
Serum glucose (mmol/L) 6.4 (5.5–7.7) 6.9 (5.6–8.4) 0.490
C-reactive protein (mg/L) 3.0 (1.5–5.6) 5.2 (2.2–9.6) 0.112
Antihypertensive therapy 75 (65.8) 12 (66.7) 0.942
Antiplatelet therapy 48 (42.1) 10 (55.5) 0.285
Time to treatment (min) with rtPA 157.0 (125.0–180.0) 144.0 (130.0–212.0) 0.605
Cardioembolic stroke 23 (20.2) 4 (22.2) 0.841
NIHSS on admission 8.0 (5.0–13.0) 14.0 (8.0–23.0) 0.005
ASPECT score on admission 10.0 (9.0–10.0) 9.5 (9.0–10.0) 0.591
FXIII activity (%) before thrombolysis 129.0 ± 36.0 107.4 ± 31.5 0.017
FXIII-A2B2 (mg/L) before thrombolysis 22.9 ± 7.8 18.6 ± 4.8 0.026
FXIII activity (%) immediately after thrombolysis 127.1 ± 33.7 110.9 ± 32.0 0.061
FXIII-A2B2 (mg/L) immediately after thrombolysis 21.8 ± 6.8 18.5 ± 6.4 0.056
FXIII activity (%) 24 h after thrombolysis 119.9 ± 33.6 91.3 ± 36.5 0.004
FXIII-A2B2 (mg/L) 24 h after thrombolysis 20.2 ± 6.2 15.1 ± 6.5 0.005
Table 5. Demographic data and FXIII levels of patients grouped according to stroke-related mortality by 
14 days post-event. Values are given as mean ± SD or median (IQR) or number (percentage). FXIII, factor 
XIII; rtPA, recombinant tissue type plasminogen activator; NIHSS, National Institute of Health Stroke Scale; 
ASPECT, Alberta Stroke Program Early CT score.
Figure 1. Changes in FXIII activity during thrombolysis in AIS patients of different outcomes by the end of the 
3rd month. FXIII activity levels are presented as mean (circles) and 95% confidence intervals (whiskers) before 
thrombolysis (A), immediately after (B) and 24 h after thrombolysis (C) in AIS patients of different outcomes by 
the end of the 3rd month. Solid circles represent patients with mRS 0–5 (n = 80), open circles indicate patients 
who did not survive (mRS 6, n = 29). **p < 0.01 (Student’s t test).
www.nature.com/scientificreports/
6SCiENTiFiC REpoRTS |  (2018) 8:7662  | DOI:10.1038/s41598-018-26025-z
levels is not entirely clear. In theory, this phenomenon might be attributed to consumption and/or degradation 
of FXIII. A likely explanation of the considerable diminution of FXIII levels post-stroke is its continuous incor-
poration into the growing thrombus, leading to consumption due to ongoing activity of the coagulation system. 
This hypothesis was suggested by an earlier pilot study, where FXIII subunit levels (but not FXIII activity) were 
measured in a group of AIS patients14. In that cohort, 41 patients received thrombolysis by rtPA or urokinase and 
their results did not differ from AIS patients not receiving thrombolytic therapy (n = 23). Moreover, in another 
study that investigated the dynamics of FXIII levels during the early phases of acute myocardial infarction in 350 
patients, a significant, transient drop of FXIII levels was observed in the majority of patients during the first five 
days post-event19. Similarly to our findings, the probability of early death was increased in those having the high-
est drop in FXIII levels (below 59.5%). As these patients did not receive thrombolytic agents, this phenomenon 
was attributed solely to consumption of FXIII associated with the evolution of infarction.
An additional mechanism for the decrease in FXIII levels observed in our study might be the proteolytic 
degradation of FXIIIa in the thrombus by plasmin or other proteases. Recently, it has been shown that activated 
FXIII, but not the zymogen form of FXIII is cleaved and inactivated by plasmin in vitro20. Less is known about 
this effect of plasmin in vivo. FXIII activity and antigen measurements performed in our study reflect circulat-
ing zymogen FXIII levels, which are not expected to be cleaved by plasmin. In fact, in our study FXIII activity 
and antigen levels measured before and immediately after thrombolysis were not significantly different, suggest-
ing that plasmin has negligible effect on zymogen FXIII in vivo. On the other hand, incorporated FXIIIa might 
become degraded and inactivated by plasmin (and/or other proteases, e.g. proteases released from polymorpho-
nuclear cells21,22) in the thrombus, attributing to the significant decrease observed in FXIII levels at 24 h post-lysis. 
Given the fact that the ELISA method used for FXIII-A2B2 determination in our study detects the intact FXIII 
tetramer complex only and no degradation products, we could not test the latter hypothesis and this must be 
investigated experimentally in future studies.
Using a logistic regression model including all potentially relevant risk factors, we found that a low FXIII 
level 24 h post-event is an independent predictor of short-term mortality (by 14 days). This result suggests that 
the reduction in FXIII levels directly relates to the pathomechanism of fatal stroke. This effect was found to be 
independent of the severity of stroke as measured by the NIHSS. Remarkably, those patients who died within the 
first week after stroke had unusually low FXIII levels the day after thrombolysis; with FXIII levels reaching only 
approximately 50% as compared to patients with better outcomes. Low FXIII levels as measured 24 h post-lysis 
were found to be associated not only with short-term but with long-term mortality (by the end of the 3rd month 
post-event) as well. However, in the logistic regression model, low FXIII levels 24 h post-lysis did not prove to be 
OR (95% CI) P value
Mortality by day 14 (n = 18)
   NIHSS score on admission 1.12 (1.02–1.23) 0.013
   FXIII activity in the lower quartile 24 h after thrombolysis 4.95 (1.31–18.68) 0.018
Mortality by the end of the 3rd month (n = 29)
   NIHSS score on admission 1.16 (1.05–1.28) 0.004
   FXIII activity in the lower quartile 24 h after thrombolysis 1.88 (0.55–6.41) 0.311
Table 6. Predictors of short-and long-term mortality in the study group. Backward multiple regression model 
included age, sex, NIHSS score on admission, active smoking, C-reactive protein levels and the categorical 
variable of factor XIII (FXIII) activity in the lower quartile as measured from samples taken 24 h after 
thrombolysis (time point C). n, number of patients; CI: confidence interval; NIHSS, National Institute of Health 
Stroke Scale.
FXIII-A p.Val34Leu FXIII-B p.His95Arg FXIII-B intron K nt29756 C>G
OR (95% CI), p-value
Stroke severity (NIHSS > 5)* 0.70 (0.32–1.54), 0.379 2.10 (0.73–6.03), 0.167 1.34 (0.56–3.25), 0.514
ICH† 2.72 (0.79–9.35), 0.112 0.17 (0.02–1.49), 0.111 0.41 (0.05–3.55), 0.673
SICH† 1.25 (0.17–8.80), 0.823 1.00 (0.09–10.97), 0.996 0.18 (0.01–3.34), 0.185
Unfavorable short-term outcome (ΔNIHSS ≥ 4)† 0.33 (0.09–1.10), 0.072 0.76 (0.22–2.66), 0.665 1.14 (0.38–3.33), 0.811
Unfavorable long-term outcome (mRS > 1)† 1.33 (0.50–3.52), 0.568 2.65 (0.85–8.26), 0.093 1.26 (0.45–3.50), 0.659
Mortality by 14 days† 0.61 (0.17–2.10), 0.434 1.84 (0.57–5.92), 0.305 1.12 (0.28–4.36), 0.871
Mortality by the end of the 3rd month† 0.45 (0.14–1.44), 0.178 1.02 (0.30–3.42), 0.975 0.91 (0.29–2.82), 0.864
Table 7. Factor XIII (FXIII) polymorphisms, stroke severity and the outcome of thrombolytic therapy. FXIII-A, 
factor XIII A subunit; FXIII-B, factor XIII B subunit; OD, odds ratio; CI, confidence interval; NIHSS, National 
Institute of Health Stroke Scale; ICH, intracranial hemorrhage (asymptomatic and symptomatic intracranial 
hemorrhage); SICH, symptomatic intracranial hemorrhage; ΔNIHSS, difference in NIHSS score by day 7; 
mRS, modified Rankin score. Short-term and long-term outcomes were assessed at 7 days and by the end of the 
3rd month post-event, respectively. *Adjustment in the statistical model to age and gender, †adjustment in the 
statistical model to age, gender and NIHSS score on admission.
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an independent predictor of long-term mortality. Post-stroke mortality at a long-term is influenced by a number 
of factors including age, co-morbidities, etc. which could explain the loss of significance in this case.
Although it is biologically plausible, low FXIII levels were not associated with therapy-associated intracranial 
bleeding in our study, indicating that hemorrhagic complications must be associated with an etiology other than 
that linked to FXIII. This finding is in compliance with the few previously published reports12,13. FXIII levels were 
not associated with stroke severity in our patient cohort. As it has been found earlier11, we also showed that FXIII 
activity was significantly higher in case of atherothrombotic stroke as compared to strokes of cardioembolic 
origin.
In this study no association was found between any of the investigated major FXIII polymorphisms with 
stroke severity, unfavorable outcomes of therapy, therapy-associated symptomatic intracranial hemorrhage and 
mortality. In case of the FXIII-A p.Val34Leu polymorphism, an interesting trend was observed showing a protec-
tive effect against unfavorable short term outcomes in carriers of the Leu allele, but results did not reach statistical 
significance. No gender-specific differences with regard to the outcome of therapy were observed in case of any 
of the investigated polymorphisms (data not shown). Among the polymorphisms investigated in the study, only 
FXIII-B intron K nt29756 G allele was associated with lower FXIII levels, but after adjustment to confounders dif-
ferences between carriers and non-carriers were not statistically significant. In a most recent study investigating 
patients with coronary sclerosis (CS) and/or myocardial infarction (MI), carriers of the FXIII-B intron K nt29756 
G allele had significantly lower FXIII levels, and the presence of the allele provided significant protection against 
CS and MI in patients with fibrinogen in the upper tertile, which prevailed only in the presence of FXIII-A Leu34 
allele18. In our study, the presence of FXIII-B intron K nt29756 G allele did not seem to have any impact on thera-
peutic outcomes, although due to the limited number of patients, it was impossible to perform subgroup analysis 
to seek for any synergistic effect between FXIII-A Leu34 and the FXIII-B intron K nt29756 G allele.
The study has limitations. Firstly, the study was designed to look for changes in FXIII levels during thromboly-
sis and to compare it with outcomes and was not designed to be a case-control study. Theoretically, we could com-
pare FXIII levels in AIS patients receiving and not receiving thrombolysis. However, while the group of patients 
receiving rtPA is a highly selected patient group with strict inclusion criteria (e.g. time-frame from symptom 
onset to treatment, age limit, absence of effective anticoagulation, etc.), the group not receiving rtPA is a group 
not meeting the inclusion criteria by definition. The important baseline differences of the two groups and the 
heterogeneity of the group not receiving thrombolysis suggest that it might not be adequate to draw conclusions 
from the comparison of these groups.
Second, the sample size in this study is limited but representative for a single-center study. In fact, when 
comparing our study with previously published literature on this subject, our study included the largest cohort of 
patients13–16. Although the number of patients with symptomatic hemorrhage was small in this cohort, the lack 
of association of hemorrhage with FXIII levels was evident. It has to be noted, that although the single-centered 
design of the study has limitations regarding patient numbers, it gave us the advantage of assured unified sample 
handling, allowing reliable and reproducible results.
In conclusion, a low FXIII level 24 h after thrombolysis in AIS patients is an independent predictor of mor-
tality by 14 days post-event. Testing FXIII levels 24 h post-lysis might help to identify patients who are at high 
risk of mortality and need altered therapeutic approach. Further studies including large number of patients are 
required to find out whether early selection of such patients could help to improve outcomes by providing better 
treatment strategies.
Methods
Study population. The study was designed as an observational study. Patients were enrolled between March 
2011 and January 2013 in a single Stroke Center (Department of Neurology, University of Debrecen, Hungary). 
Study population included 132 consecutive patients admitted with AIS within 4.5 h of their symptom onset. All 
patients underwent intravenous (i.v.) thrombolytic therapy using recombinant tissue plasminogen activator 
(rtPA, Alteplase, Boehringer Ingelheim, Germany) according to the European Stroke Organization guidelines5. 
Patients or their relatives had been informed about the study and gave written informed consent. Ethical approval 
was obtained by the Ethics Committee of University of Debrecen, Debrecen, Hungary. All investigations and 
methods were performed in accordance with the relevant guidelines and regulations.
Blood sampling and laboratory measurements. Peripheral blood samples were drawn from patients 
into vacutainer tubes. Tubes with no anticoagulant were used for routine clinical chemistry tests, tubes antico-
agulated with K3-EDTA for complete blood count, tubes containing 0.109 M sodium citrate or CTAD (buffered 
citrate, theophylline, adenosine and dypiridamole) for hemostasis tests (Becton Dickinson, Franklin Lakes, NJ). 
Blood samples were collected on three different occasions: upon hospital admission (before thrombolysis) (time 
point A), immediately after the administration of rtPA infusion (64 ± 10 min, time point B) and approximately 
24 h after the administration of thrombolytic therapy (time point C). Routine blood count and chemistry tests 
were performed only from samples collected at time point A. Chemistry tests included the measurements of 
serum ions, glucose levels, basic kidney function tests, liver function tests and high sensivity C-reactive protein 
(CRP) measurements (Roche Diagnostics, Mannheim, Germany). Prothrombin time (PT) and activated partial 
thromboplastin time (APTT) were determined at time point A while thrombin time (TT) was measured on all 
three occasions by routine methods (Siemens AG, Erlangen, Germany). Plasma from CTAD tubes was separated 
by centrifugation (1500 g, 20 min) and samples were stored at −70 °C until further analysis.
Plasma levels of FXIII activity were determined by ammonia release assay23 using a commercially availa-
ble reagent kit (REA-chrom FXIII kit, Reanal-ker, Budapest, Hungary, reference range: 69–143%, CV: 3.8%). 
FXIII-A2B2 antigen levels were determined by a sandwich enzyme-linked immunosorbent assay (ELISA), 
comprising of a biotinylated monoclonal capture-antibody against the B-subunit and a peroxidase-labelled 
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monoclonal tag-antibody against the A-subunit (reference range: 14–28 mg/l, CV: 2.0%)24. DNA isolation was 
performed from buffy coat of CTAD blood samples by QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). 
FXIII-A p.Val34Leu (c.103 G > T; rs5985), FXIII-A p.Tyr204Phe (c.614 A > T; rs3024477), FXIII-B p.His95Arg 
(c.344 G > A; rs6003) and FXIII-B Intron K (IVS11 c.1952 + 144 C > G; rs12134960) polymorphisms were deter-
mined by in-house developed real-time PCR methods25,26 using fluorescence resonance energy transfer (FRET) 
detection and melting curve analysis on a LightCycler® 480 instrument (Roche Diagnostics GmbH, Mannheim, 
Germany). Sanger sequencing was carried out to identify mutations in the exons, flanking intronic regions and 
in the promoter of F13A1 using an ABI3130 Genetic Analyzer and Sequencing Analysis 5.4 software (Thermo 
Fisher Scientific, Carlsbad, CA) in a single patient with considerably low FXIII levels (<50%) at time point A and 
bleeding complications. All primers are available from the authors upon request.
Clinical data. Neurological deficit of patients was determined by the National Institute of Health Stroke 
Scale (NIHSS) score27 on admission (before thrombolysis), 2 h, 24 h, and 7 days after thrombolytic therapy. Upon 
admission, all patients underwent computer tomography brain scan (CT) and computer tomography angiogra-
phy (CTA) to ensure the diagnosis of acute ischemic stroke. Stroke etiology was classified according to the Trial 
of Org 10172 in Acute Stroke Treatment TOAST criteria28. A follow-up CT was performed for every patient 
24 h after rtPA infusion. Hemorrhagic events on the follow-up CT scan were classified as symptomatic (SICH) 
or asymptomatic intracranial hemorrhage (aSICH) according to the European Cooperative Acute Stroke Study 
(ECASS) II criteria13,29,30. CT images taken before and 24 h after thrombolysis were analyzed simultaneously by 4 
different investigators and the ASPECT scores were calculated31,32. For each patient the time of symptom onset, 
demographic and clinical characteristics (i.e.: cardiovascular risk factors, previous medication, neurological sta-
tus, smoking habits) were recorded upon admission. Patients were followed and at 3 months after the event the 
modified Rankin score (mRS)33 was determined.
The following outcomes were investigated: 1/short-term functional outcome (by day 7 post-event), 2/
long-term functional outcome (by the end of the 3rd month post-event), 3/stroke-associated mortality by day 7, 
day 14 and by the end of the 3rd month post-event, 4/the presence of therapy-associated symptomatic or asymp-
tomatic intracranial bleeding (according to ECASS II criteria). Unfavorable short-term outcome was defined as 
an increase in NIHSS score by at least 4 points by day 7. Unfavorable long-term functional outcome was defined 
as an mRS score greater than 1 at 3 months post-event.
Statistical analysis. Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS, Release 22.0, Chicago, IL). Distribution of continuous variables was tested by the Kolmogorov-Smirnov 
test. Parametric variables were expressed as mean ± SD, non-parametric variables were presented as median 
(interquartile range) unless otherwise stated. In case of two-group analyses Student’s t-test or in case of 
non-parametric data Mann-Whitney U test was applied. Strength of association between variables was tested 
using Pearson’s correlation test. Multiple linear regression analysis was performed to adjust for parameters inde-
pendently associated with FXIII levels. ANOVA using the Bonferroni correction was applied for multiple com-
parisons. Differences between categorical variables were assessed by the χ2 test. Logistic regression model was 
used to analyze the effect of FXIII levels and FXIII polymorphisms on various outcomes, results were expressed as 
odds ratio (OR) and 95% confidence interval (95% CI). When testing for independent risk factors of mortality, all 
potentially relevant risk factors (e.g. age, gender, stroke severity, smoking, CRP levels, NIHSS score on admission) 
were included in a multivariable backward conditional stepwise logistic regression model. Results were consid-
ered statistically significant when p < 0.05.
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